Satellite Symposia
The following independent satellite symposia will take place in conjunction with the 2019 Meeting on Hematologic Malignancies (MHM). There is no fee to attend; and registration to MHM is not required to participate in the symposia.
Targeting B-cell Maturation Antigen (BCMA) in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context
Friday, September 6, 2019, 7:00 – 10:00 p.m.
Fairmont Chicago, Millennium Park, Chicago, IL – Rouge Room
Awareness and knowledge of B-cell maturation antigen (BCMA) as a therapeutic target remains limited among clinicians who provide care for patients with relapsed/refractory multiple myeloma (MM). However, the number of clinical trials evaluating these therapies is rapidly increasing; and a few have even received breakthrough therapy status. This creates a need among clinicians for education that provides a better understanding of BCMA as a target, along with an improved knowledge of emerging efficacy and safety data that may soon inform the use of these promising strategies in clinical practice. As such, The University of Texas MD Anderson Cancer Center Department of CME/ Conference Management and its partner, MediCom Worldwide, have designed a comprehensive educational curriculum to be presented at the 2019 ASH Meeting on Hematologic Malignancies.
Innovative Therapy for B-Cell Malignancies: A MasterClass and Tumor Board on Decision-Making in CLL, FL, and MCL
Friday, September 6, 2019, 7:00 – 10:00 p.m.
Fairmont Chicago, Millennium Park, Chicago, IL – Gold Room
Recent science has validated the use of multiple novel agent classes, including BTK and PI3K inhibitors, next-generation antibodies, immunomodulating drugs, and BCL-2 inhibitors, and transformed the therapeutic landscape for chronic lymphocytic leukemia, mantle cell lymphoma, and follicular lymphoma. In the wake of these developments, standard practice is in a state of flux, as new choices in upfront therapy, novel chemotherapy-sparing combinations, personalized immunotherapy, and sequential strategies based on targeted agents promise to upend decades of clinical consensus.
BTK Inhibitors for CLL: Clinical Pearls and Future Directions
Saturday, September 7, 2019, 7:00 p.m. – 10:00 p.m.
Fairmont Chicago, Millennium Park, Chicago, IL – Rouge Room
This live symposium is designed to aid community and academic hematologists/oncologists in differentiating among available Bruton’s tyrosine kinase (BTK) inhibitors that are used to treat patients with chronic lymphocytic leukemia (CLL). The similarities and differences between first- and second-generation BTK inhibitors will be discussed. The expert faculty will present the clinical trial data and will provide guidance on the role of BTK inhibitors for the management of treatment-naive and previously treated CLL. Future directions and late-stage emerging BTK inhibitors will also be covered.